Geeta Devgan
Overview
Explore the profile of Geeta Devgan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
807
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lloyd J, Zomorodian N, Devgan G, Batten J
Clin J Oncol Nurs
. 2024 Sep;
28(5):483-491.
PMID: 39324718
Background: About one-quarter of patients with advanced prostate cancer have alterations in homologous recombination repair (HRR) genes. In a global phase 3 study, talazoparib plus enzalutamide significantly improved progression-free survival...
2.
McKay R, Morgans A, Shore N, Dunshee C, Devgan G, Agarwal N
Cancer Treat Rev
. 2024 Apr;
126:102726.
PMID: 38613872
Introduction: Metastatic castration-resistant prostate cancer (mCRPC) remains incurable and develops from biochemically recurrent PC treated with androgen deprivation therapy (ADT) following definitive therapy for localized PC, or from metastatic castration-sensitive...
3.
Gupta S, Costantino H, Ike C, Gupta S, Bhanegaonkar A, Su C, et al.
Oncologist
. 2023 Oct;
29(3):244-253.
PMID: 37846191
Background: The treatment landscape for locally advanced/metastatic urothelial carcinoma (la/mUC) has evolved. This study examined US prescribing patterns and clinical decision-making for first-line (1L) and first-line maintenance (1LM) treatment. Materials...
4.
Lapuente M, Conway D, Wood L, Kehoe K, Carroll Bullock A, Devgan G, et al.
Clin J Oncol Nurs
. 2023 Sep;
27(1):71-80.
PMID: 37677821
Background: The phase 3 of JAVELIN Bladder 100 trial demonstrated that avelumab first-line (1L) maintenance in addition to best supportive care significantly prolonged overall survival compared to best supportive care...
5.
Wood L, Conway D, Lapuente M, Salvador G, Fernandez Gomez S, Carroll Bullock A, et al.
J Infus Nurs
. 2022 May;
45(3):142-153.
PMID: 35537002
Immune checkpoint inhibitors, such as programmed cell death ligand 1 inhibitors pembrolizumab, nivolumab, atezolizumab, and avelumab, are used to treat patients with advanced urothelial carcinoma (UC). Based on data from...
6.
George S, Bell E, Zheng Y, Kim R, White J, Devgan G, et al.
Oncologist
. 2021 May;
26(7):e1205-e1215.
PMID: 33955118
Background: We investigated the association between adverse events (AEs) suspected to be immune-related and health care resource utilization, costs, and mortality among patients receiving programmed cell death 1/programmed cell death...
7.
Grivas P, Agarwal N, Pal S, Kalebasty A, Sridhar S, Smith J, et al.
Cancer Treat Rev
. 2021 Apr;
97:102187.
PMID: 33839438
Although urothelial carcinoma (UC) is considered a chemotherapy-sensitive tumor, progression-free survival and overall survival (OS) are typically short following standard first-line (1L) platinum-containing chemotherapy in patients with locally advanced or...
8.
Reed M, Rosales A, Chioda M, Parker L, Devgan G, Kettle J
Adv Ther
. 2020 May;
37(6):3019-3030.
PMID: 32399810
Resistance to first- and second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) and development and progression of central nervous system metastases remain significant issues in the treatment of ALK-positive...
9.
Corral J, Mok T, Nakagawa K, Rosell R, Lee K, Migliorino M, et al.
Future Oncol
. 2019 Jul;
15(24):2795-2805.
PMID: 31313942
We evaluated reasons for dacomitinib dose reduction (DR) and examined adverse event (AE) incidence, key efficacy end points (progression-free survival [PFS]/overall survival [OS]), and pharmacokinetics in dose-reducing patients in the...
10.
Pujade-Lauraine E, Fujiwara K, Dychter S, Devgan G, Monk B
Future Oncol
. 2018 Mar;
14(21):2103-2113.
PMID: 29584456
Avelumab is a human anti-PD-L1 checkpoint inhibitor with clinical activity in multiple solid tumors. Here, we describe the rationale and design for JAVELIN Ovarian 200 (NCT02580058), the first randomized Phase...